Find clinical trials
Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.
599 clinical trials found
Clinical trials
PERFORM-CPR
Personalised Exercise Rehabilitation FOR people with multimorbidity (ACTRN12624001191583)
Many people in Australia are living with multiple long-term health conditions such as heart and lung disease, diabetes, arthritis, stroke, depression, and cancer. Exercise-based rehabilitation may help people with chronic conditions improve their physical function, symptoms and quality of life and help them spend less time in the hospital. However, until now there have been few exercise options for people living with multiple long-term health conditions. We are now conducting a study to see if a personalised rehabilitation program (PERFORM trial), which includes exercises and education sessions, can improve wellbeing and physical function better than usual care in people with multiple long-term health conditions.
Currently recruiting
PERSONAL
PERsonalised Selection Of medication for Newly diagnosed Adult epiLepsy (ACTRN12623000209695)
Currently recruiting
Pfizer B7981080
No longer recruiting
PoCeMR
Development of Clinical Utility for Point of Care MRI (Trial Not Registered)
Currently recruiting
Portico IDE
Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial (PORTICO)
The PORTICO pivotal IDE trial is a prospective, multi-center, randomized, controlled clinical investigation study designed to evaluate the safety and effectiveness of the SJM Portico Transcatheter Heart Valve and Delivery Systems (Portico) via transfemoral and alternative delivery methods in high-risk and extreme-risk patients.
Currently recruiting
Portico NG
The primary objective of this clinical study is to evaluate the acute safety and
effectiveness of the Navitor Transcatheter Aortic Heart Valve as assessed by the rate of all-cause mortality at 30 days and the rate of moderate or greater paravalvular leak at 30 days. The results from this study will be descriptively compared to the data from the first-generation Portico Transcatheter Aortic Heart Valve and commercially available TAVI devices studied in the same patient population (e.g. high and extreme surgical risk).
Currently recruiting